Tech Company Financing Transactions
ABclonal Biotechnology Funding Round
On 2/23/2021, ABclonal Biotechnology received $93 million in Series C funding from Lyfe Capital, Sequoia Capital and Kinghall Ventures.
Transaction Overview
Company Name
Announced On
2/23/2021
Transaction Type
Venture Equity
Amount
$93,000,000
Round
Series C
Investors
Lyfe Capital (Lead Investor)
Sequoia Capital (Lead Investor)
Proceeds Purpose
The company intends to use the funds to accelerate its research and development pipeline for in vitro diagnostic raw materials and expand production capabilities of its research reagent products and services.
Company Information
Company Status
Private & Independent
Industry
Healthcare IT
Mailing Address
500W Cummings Park 6500
Woburn, MA 01801
USA
Woburn, MA 01801
USA
Phone
Website
Email Address
Overview
Based in Massachusetts, ABclonal is a dynamic and growing provider of biology research reagents and services. With scientists from world-class universities, we thrive to improve the quality of life science research by providing high-quality antibodies, proteins, ELISA kits, NGS Prep Kits and molecular enzymes.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Zack Wu
Browse more venture capital transactions:
Prev: 2/23/2021: Splice venture capital transaction
Next: 2/24/2021: Aviatrix Systems venture capital transaction
Share this article
News on VC Transactions
We do our best to record every notable VC transaction. VC investment data records on this site are derived from publicly available VC deal announcements. The data comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs